GAMMA Investing LLC Has $4.52 Million Holdings in LeMaitre Vascular, Inc. (NASDAQ:LMAT)

GAMMA Investing LLC increased its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT - Free Report) by 7,486.5% during the first quarter, according to its most recent Form 13F filing with the SEC. The firm owned 53,864 shares of the medical instruments supplier's stock after purchasing an additional 53,154 shares during the period. GAMMA Investing LLC owned approximately 0.24% of LeMaitre Vascular worth $4,519,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Smartleaf Asset Management LLC increased its holdings in LeMaitre Vascular by 234.4% in the 4th quarter. Smartleaf Asset Management LLC now owns 418 shares of the medical instruments supplier's stock valued at $39,000 after buying an additional 293 shares during the period. CBIZ Investment Advisory Services LLC boosted its position in shares of LeMaitre Vascular by 38.5% during the 4th quarter. CBIZ Investment Advisory Services LLC now owns 421 shares of the medical instruments supplier's stock worth $39,000 after acquiring an additional 117 shares in the last quarter. Huntington National Bank boosted its position in shares of LeMaitre Vascular by 64.9% during the 4th quarter. Huntington National Bank now owns 1,156 shares of the medical instruments supplier's stock worth $107,000 after acquiring an additional 455 shares in the last quarter. Empowered Funds LLC bought a new position in LeMaitre Vascular in the fourth quarter valued at approximately $150,000. Finally, Canada Pension Plan Investment Board raised its position in LeMaitre Vascular by 112.5% during the fourth quarter. Canada Pension Plan Investment Board now owns 1,700 shares of the medical instruments supplier's stock valued at $157,000 after purchasing an additional 900 shares in the last quarter. Institutional investors and hedge funds own 84.64% of the company's stock.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on LMAT. Lake Street Capital raised their target price on LeMaitre Vascular from $105.00 to $110.00 and gave the company a "buy" rating in a report on Friday, February 28th. Barrington Research lowered LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research note on Friday, February 28th. Oppenheimer cut LeMaitre Vascular from an "outperform" rating to a "market perform" rating in a research report on Friday, February 28th. Finally, Wells Fargo & Company initiated coverage on shares of LeMaitre Vascular in a report on Thursday, February 13th. They issued an "equal weight" rating and a $95.00 target price for the company. Five equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, LeMaitre Vascular presently has an average rating of "Hold" and an average target price of $97.83.

LeMaitre Vascular Stock Performance

Shares of LMAT traded down $0.81 during trading hours on Thursday, reaching $82.33. The stock had a trading volume of 12,031 shares, compared to its average volume of 167,960. LeMaitre Vascular, Inc. has a 12 month low of $71.42 and a 12 month high of $109.58. The stock has a market capitalization of $1.86 billion, a PE ratio of 44.99, a PEG ratio of 2.22 and a beta of 0.83. The company's 50-day moving average is $83.75 and its two-hundred day moving average is $90.64.

LeMaitre Vascular (NASDAQ:LMAT - Get Free Report) last issued its earnings results on Thursday, May 1st. The medical instruments supplier reported $0.48 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.50 by ($0.02). LeMaitre Vascular had a return on equity of 13.15% and a net margin of 19.40%. The firm had revenue of $59.87 million during the quarter, compared to analyst estimates of $57.61 million. During the same period in the previous year, the company earned $0.44 EPS. LeMaitre Vascular's revenue for the quarter was up 12.0% on a year-over-year basis. Equities analysts anticipate that LeMaitre Vascular, Inc. will post 1.94 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, May 29th. Investors of record on Thursday, May 15th were given a dividend of $0.20 per share. The ex-dividend date of this dividend was Thursday, May 15th. This represents a $0.80 annualized dividend and a yield of 0.97%. LeMaitre Vascular's dividend payout ratio is presently 40.40%.

Insiders Place Their Bets

In related news, CEO George W. Lemaitre sold 76,868 shares of the firm's stock in a transaction on Monday, May 19th. The stock was sold at an average price of $85.79, for a total transaction of $6,594,505.72. Following the completion of the transaction, the chief executive officer now directly owns 1,796,783 shares of the company's stock, valued at $154,146,013.57. This trade represents a 4.10% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Insiders have sold 100,000 shares of company stock valued at $8,556,857 in the last ninety days. 9.50% of the stock is currently owned by insiders.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.